Destiny Pharma to present clinical study data at infectious diseases congress


Destiny Pharma PLC (LON:DEST), the biotechnology company focused on the development of novel medicines to prevent life-threatening infections, will present data from its successful Phase 2b clinical study of XF-73 nasal gel at the 2021 ECCMID congress.

An abstract providing analysis and discussion of the late-breaking data arising from the study was accepted for presentation at Europe’s premier antimicrobials congress, the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID).

The congress will be held from July 9 to July 12 of this year.

READ Destiny Pharma says anti-infection gel trial results ‘exceptionally high’


Please enter your comment!
Please enter your name here